Fig. 3
Mean plasma-concentration–time profiles of JNJ-61393215 on day 1 (a, linear [SD]) and day 7 (b, semilogarithmic) following multiple oral doses of 5, 15, 45, and 90 mg of JNJ-61393215 QD in healthy male participants (Part 1).
Fig. 3 | Translational Psychiatry
